A number of media sources have covered new developments in the biosimilars space.  Here is a round-up of some highlights from this month.

Reuters reports that biosimilars, including biosimilar versions of Rituxan and Herceptin, have begun to capture a large portion of the British biosimilar market, whereas approvals and adoptions in the United States have lagged behind Britain.  Additional reporting from Reuters discusses how the FDA has approximately a dozen policies in the works to increase the use of biosimilars in the US, according to agency head Scott Gottlieb.

The Boston Globe discusses bipartisan support for the CREATES Act, which aims to disallow brand-name drug makers from declining to sell samples to potential generic and biosimilar competitors, based on the side effects of the branded products.

As reported by the Wall Street Journal, earlier this month, the Trump administration overturned an Obama-era policy that rewarded doctors who prescribed biosimilars instead of more costly brand name products.

As reported in the United European Gastroenterology Journal, authors of a recent study conclude that the biosimilar infliximab should be the first choice in treating fistulizing Crohn’s disease.

IQVIA has issued a report on predicted changes in global healthcare, including the growth potential for biotherapeutics.